Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 + Aumolertinib vs Aumolertinib in 1L EGFR-mutated NSCLC
NCT07183189Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2025
- Primary completion
- Nov 2032
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Oct 2025; status: active, not recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07183189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183189.